Department of Anesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Zhejiang Province, China.
Department of Anesthesiology, Second Affiliated Hospital of Wenzhou Medical University, Zhejiang Province, China.
Pain Physician. 2021 Mar;24(2):E161-E168.
The erector spinae plane block (ESPB) is gaining popularity in lumbar fusion for postoperative pain management.
The aim of this study was to investigate the changes of opioid consumption after surgery, the range of cold temperature sensory blockade, pain, and safety.
Randomized controlled study.
Single center.
Patients who were randomized to ESPB with 0.375% ropivacaine (ropivacaine group) and mock ESPB with saline (saline group) and underwent posterior lumbar fusion surgery. The primary endpoint was the total dosage of oxycodone. Secondary endpoints included remifentanil consumption, postoperative pain scores, postoperative adverse events, safety, and range of cold hypoesthesia.
Oxycodone consumption in the first 48 hours after surgery was significantly lower in the ropivacaine group than in the saline group (P < 0.05). Remifentanil consumption was significantly lower in the ropivacaine group compared with the saline group during the surgery (0.69 ± 0.03 mg vs. 0.85 ± 0.04 mg, P < 0.05). The areas of cold hypoesthesia were identified in the ropivacaine group after the block, but not in the saline group. Rest and exercise pain scores after surgery were significantly lower in the ropivacaine group than in the saline group (P < 0.05). The overall safety of the ropivacaine group were generally comparable to that of the saline group.
The areas of cold hypoesthesia were tested at different time points after ESPB, but the area of sensory loss was not tested, and the recovery of postoperative sensation was not recorded. In addition, we tested only temperature sensation, but not acupuncture pain.
Ultrasound-guided lumbar ESPB reduces the amount of analgesics required during and after lumbar fusion and reduces the postoperative Visual Analog Scale pain score.
竖脊肌平面阻滞(ESPB)在腰椎融合术后疼痛管理中越来越受欢迎。
本研究旨在探讨术后阿片类药物消耗、冷觉感觉阻滞范围、疼痛和安全性的变化。
随机对照研究。
单中心。
随机分为接受 0.375%罗哌卡因 ESPB(罗哌卡因组)和生理盐水 ESPB(生理盐水组)的患者,并接受后路腰椎融合术。主要终点是羟考酮的总剂量。次要终点包括瑞芬太尼消耗、术后疼痛评分、术后不良反应、安全性和冷感觉减退范围。
术后 48 小时内,罗哌卡因组羟考酮消耗明显低于生理盐水组(P < 0.05)。与生理盐水组相比,罗哌卡因组术中瑞芬太尼消耗明显减少(0.69 ± 0.03 mg 比 0.85 ± 0.04 mg,P < 0.05)。阻滞后可在罗哌卡因组识别出冷感觉减退区域,但在生理盐水组未识别出。与生理盐水组相比,术后休息和运动疼痛评分在罗哌卡因组明显降低(P < 0.05)。罗哌卡因组的总体安全性一般与生理盐水组相当。
冷感觉减退区域在 ESPB 后不同时间点进行测试,但未测试感觉丧失区域,也未记录术后感觉恢复情况。此外,我们仅测试了温度感觉,而不是针刺疼痛。
超声引导下腰椎 ESPB 可减少腰椎融合术中及术后阿片类药物的用量,并降低术后视觉模拟评分疼痛。